Praxis Precision Medicines, Inc. PRAX

PRAX Company Overview

Praxis Precision Medicines, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders linked to dysfunctional neuronal excitation and inhibition. The company operates within the biotechnology and precision medicine industries, with a primary emphasis on rare genetic epilepsies, movement disorders, and neuropsychiatric conditions. Praxis uses a translational medicine approach that combines human genetics, molecular biology, and neurophysiology to identify and develop targeted therapies intended to modulate neuronal network activity.

The company’s principal value drivers are its pipeline candidates targeting sodium channel and GABA receptor pathways, including therapies under development for developmental and epileptic encephalopathies, essential tremor, and related neurological disorders. Praxis has positioned itself as a precision neuroscience company with an emphasis on genetically informed drug development and biomarker-driven clinical programs. Founded in 2015 and headquartered in Boston, Massachusetts, the company expanded through internal research, licensing arrangements, and acquisitions, including the acquisition of Epalex Corporation, which broadened its developmental capabilities in rare neurology.